Icu Medical Inc

Health Care
Medical/Dental Instruments
www.icumed.com

Earnings Score
Moat Score
Safety Score

Market Cap $3.79B
PE -34
Debt $1.66B
Cash $312.51M
EV $5.14B
FCF $169.88M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$111.01M
EBIT	$25.85M
ROE	-5%
ROA	1%
FCF	$169.88M
Equity	$2.05B
Growth Stability	-77%
PE	-34.17
PEG	9.88
PB	1.85
P/FCF	22.33
P/S	1.62
Price/Cash	0.08
Debt/Equity	0.81
Debt/FCF	9.78
Net Margins	-5%
Gross Margins	33%
Op. Margins	1%
Earnings CAGR	0%
Sales Growth YoY	6%
Sales Growth QoQ	-1%
Sales CAGR	21%
FCF CAGR	4%
Equity CAGR	16%
Earnings Stability	0
Earnings Growth YoY	-556%
Earnings Growth QoQ	54%

Earnings CAGR 5Y	-3%
Sales CAGR 5Y	19%
FCF CAGR 5Y	10%
Equity CAGR 5Y	11%
Earnings CAGR 3Y	18%
Sales CAGR 3Y	18%
FCF CAGR 3Y	13%
Equity CAGR 3Y	3%
Market Cap	$3.79B
Revenue	$2.34B
Assets	$4.31B
Total Debt	$1.66B
Cash	$312.51M
Shares Outstanding	24.35M
EV	5.14B
Earnings Score	6%
Moat Score	11%
Safety Score	46%
Final Score	21%
Working Capital	708.5M
Current Ratio	2.29
Gross Profit	$769.11M
Shares Growth 3y	3%
Equity Growth QoQ	1%
Equity Growth YoY	-2%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

ICU Medical is a California-based, pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. After ICU's acquisition of Hospira Infusion Systems from Pfizer in 2017, it became one of the largest players in this concentrated industry, holding top-tier positions in its major reporting segments: infusion consumables (37% of 2020 revenue), IV solutions (31%), infusion systems (28%), and critical care (4%). The combined entity remains primarily U.S. focused, generating over 70% of its sales domestically.

SEC Filings

Direct access to Icu Medical Inc (ICUI) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Icu Medical Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Icu Medical Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 0%

Stability 0%

loading chart...

Icu Medical Inc Discounted Cash Flow

Fully customizable DCF calculator online for Icu Medical Inc.

Years

Calculation mode

= $2.3B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$170M	$177M	$185M	$194M	$202M	$212M	$221M	$231M	$241M	$252M	$263M	$2.6B
DCF		$161M	$153M	$146M	$138M	$131M	$125M	$118M	$113M	$107M	$102M	$1B
Value	$2.3B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	9%	13%	17%	5%	2%	8%	7%	8%	-3%	-1%	-5%
ROA	-	11%	12%	4%	1%	7%	6%	7%	-1%	1%	1%
ROE	-	8%	10%	6%	2%	7%	6%	6%	-4%	-1%	-5%

Bad Net Margins (-5.36%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	0	-	-	0	-	0	-11.2	20.64	9.78
Debt over Equity	-	-	0	-	-	0	-	0	0.82	0.8	0.81
Growth Stability	-	-	-	100%	49%	100%	100%	100%	-77%	-77%	-77%

Bad Debt/FCF ratio (9.78)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Good Debt/Equity ratio (0.81)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (-77%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	10%	11%	241%	8%	-10%	0%	4%	73%	-1%	19%
Earnings YoY growth	-	71%	40%	9%	-58%	251%	-14%	19%	-172%	-60%	-3%
Equity YoY growth	-	14%	14%	82%	5%	9%	9%	8%	29%	2%	11%
FCF YoY growth	-	-5%	59%	20%	-16%	-93%	3K%	52%	-177%	-154%	10%